BSE · 524661
Welcure Drugs & Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹26 Cr with net profit ₹2 Cr — a 8.2% net margin, versus -186.16% the period before.
Shareholding
As of 2026-03-31
- Public100%
87,977 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 5.91× from low to high.
Risk flags
Derived from disclosed data
- 52-week range spans 5.91× (₹0.22 to ₹1.3) — an unusually wide band.
Peer comparison
Trading · ranked #314 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,95,202 Cr | 24.35 | 4.85 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,51,742 Cr | 382.57 | 10.29 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,59,874 Cr | 92.62 | 22.89 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹94,893 Cr | 1227.22 | 65.98 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,591 Cr | 56.84 | 6.81 | 11.32% | 6.61% |
| Aegis Logistics Limited | ₹44,770 Cr | 109.11 | 7.39 | 14.83% | 10.78% |
| Premier Energies Limited | ₹44,701 Cr | 29.61 | 10.38 | 35.05% | 19.3% |
| Aditya Infotech Limited | ₹39,093 Cr | 230.84 | 20.82 | 19.61% | 8.72% |
| Redington Limited | ₹24,614 Cr | 15.46 | 2.42 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,629 Cr | 211.08 | 10.36 | 14.16% | 8.36% |
| Welcure Drugs & Pharmaceuticals Ltd.(this company) | ₹30 Cr | — | 0.31 | -5.66% | -4.65% |
AI analysis
AI-generated · google/gemini-2.5-flashWelcure Drugs & Pharmaceuticals Ltd. is listed with a market capitalization of Rs 32 Cr. The company reported revenue of Rs 26.46 Cr and a negative profit margin of -464.8%. Its earnings per share (EPS) is 0 and its return on equity (ROE) is -5.66%.
Positives
- +The debt-to-equity ratio is 0.42, indicating a moderate level of debt.
- +Annual revenue increased significantly from Rs 0.0939 Cr in Mar 2024 to Rs 26.4599 Cr in Mar 2025.
- +Net profit improved to Rs 2.1701 Cr in Mar 2025, from a loss of Rs -0.1748 Cr in Mar 2024.
Negatives
- −The company has a negative profit margin of -464.8%.
- −Return on equity (ROE) is negative at -5.66%.
- −Return on capital employed (ROCE) is negative at -5.6587%.
- −Promoter holding is 0%, as of Mar 2026.
- −The company reported zero revenue for Dec 2025 and Mar 2026 quarters, with a net loss of Rs -49.86 Cr in Mar 2026.
Financial performance
Welcure Drugs & Pharmaceuticals Ltd. reported an annual revenue of Rs 26.4599 Cr in Mar 2025. This marks a substantial increase from Rs 0.0939 Cr in Mar 2024. Net profit increased to Rs 2.1701 Cr in Mar 2025, from a loss of Rs -0.1748 Cr in Mar 2024. Quarterly revenue showed significant fluctuation, with Rs 299.91 Cr in Jun 2025 and Rs 0 Cr in Dec 2025 and Mar 2026.
Profitability & Returns
The company's profit margin stands at -464.8%. Return on equity (ROE) is -5.66% and return on capital employed (ROCE) is -5.6587%. The earnings per share (EPS) is reported as 0. Annual EPS has varied, from 0.05 in Mar 2021 to 0.36 in Mar 2025, declining to -0.13 in Mar 2024 before the rise.
Balance Sheet
The debt-to-equity ratio of Welcure Drugs & Pharmaceuticals Ltd. is 0.42, indicating a moderate level of debt relative to equity. The book value per share is Rs 0.79. The company's market capitalization is Rs 32 Cr.
Ownership & Pledges
As of Mar 2026, public shareholding in Welcure Drugs & Pharmaceuticals Ltd. is 100%. Promoter holding is 0%, with no shares pledged. There is no reported holding by Domestic Institutional Investors (DII) or Foreign Institutional Investors (FII). The total number of shareholders was 87977 in Mar 2026.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Welcure Drugs & Pharmaceuticals Ltd.share price & fundamentals